When Will Retatrutide Be Approved?
When Will Retatrutide Be Approved?
Short answer: Retatrutide is not yet approved. Third-party timeline estimates suggest an FDA approval decision around late 2027, with a possible commercial launch in 2028, if the Phase 3 trials and FDA review proceed normally. Lilly has not announced an official approval date. These are estimates and could shift.
Where retatrutide is in the approval process
Retatrutide is in Phase 3 clinical trials — the TRIUMPH program, run by Eli Lilly. Phase 3 is the final stage of testing before a company can submit a drug for approval. The key trials:
- TRIUMPH-1 — obesity in adults without diabetes (n=2,339). Reported ~28.3% weight loss at 80 weeks on 12 mg (Lilly).
- TRIUMPH-4 — obesity, reporting ~28.7% weight loss at 68 weeks (GLP-3 Wiki).
- TRANSCEND-T2D-1 — type 2 diabetes, with results presented at ADA in June 2026.
- TRIUMPH-Outcomes — a long-term cardiovascular and renal outcomes trial (CVOT) still ongoing in 2026 (GLP-3 Wiki).
Estimated timeline
| Milestone | Estimated timing | Status |
|---|---|---|
| Phase 3 trials (TRIUMPH program) | 2023–2026 | Ongoing / reporting |
| NDA submission to FDA | Late 2026 – early 2027 | Anticipated |
| FDA review (~10–12 months) | 2027 | Pending filing |
| FDA approval decision | Late 2027 (estimated) | Estimated |
| Commercial launch | 2028 (estimated) | Estimated |
Third-party timeline estimates; Lilly has not announced an official approval date. Source: GLP-3 Wiki — FDA approval timeline
Important caveats
- These are estimates, not promises. Drug approvals routinely slip by a year or more due to trial delays, FDA review questions, or manufacturing issues.
- The CVOT (TRIUMPH-Outcomes) may influence timing — regulators pay close attention to cardiovascular safety for weight-loss drugs, and the glucagon receptor's effect on heart rate is being watched (GLP-3 Wiki).
- Even after approval, supply of new GLP-1 drugs has historically been constrained (as seen with Wegovy and Zepbound), so "approved" and "easily available by prescription" may not arrive at the same time.
If you want a notification when key milestones hit — NDA filing, FDA decision, launch — sign up for the Retawiz waitlist and we'll alert you.
Retawiz provides educational information only and is not medical advice. Dates are estimates based on publicly available information and may change. Retatrutide is investigational and not FDA-approved. Retawiz does not sell, source, or recommend any medication.